Sensorion secures approval for HearConnex Phase I/II study in France

Phase 1approvedSENS-601Positive

AI Analysis

Summary

Sensorion has received French ANSM authorization to initiate the HearConnex Phase I/II clinical trial evaluating its gene therapy SENS-601 for hearing loss caused by GJB2 gene mutations.

Clinical Trial Data

Phase

Phase I/II

Outcome Details

French ANSM authorization received for HearConnex Phase I/II clinical trial

Importance:5/10

Sentiment:

0.70

gene therapyhearing lossregulatory approvalFranceGJB2

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 4, 2026 8:30 AM

Read Original